Cargando…

Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report

INTRODUCTION: Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we do not have any effective treatment for the metastatic disease apart from surgi...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalaki, Vasiliki, Gennatas, Constantine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350425/
https://www.ncbi.nlm.nih.gov/pubmed/22524151
http://dx.doi.org/10.1186/1752-1947-6-115
_version_ 1782232660923383808
author Michalaki, Vasiliki
Gennatas, Constantine
author_facet Michalaki, Vasiliki
Gennatas, Constantine
author_sort Michalaki, Vasiliki
collection PubMed
description INTRODUCTION: Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Current strategies are based on results obtained in the context of clear cell-type renal cell carcinoma. Separate trials for rare histologies seem unfeasible and are unlikely to be performed. For these cases, clinical observations are an important part for advancing therapeutic insight. In recent years, novel tyrosine kinase inhibitors have been shown to have significant clinical benefit in advanced renal cell carcinoma. CASE PRESENTATION: We present the case of a 43-year-old Caucasian man with advanced chromophobe renal cell carcinoma treated with the tyrosine kinase inhibitor sunitinib and subsequently with sorafenib and the mammalian target of the rapamycin inhibitor everolimus, achieving a prolonged response and significant clinical benefit. We report an unexpectedly high efficacy of everolimus as a third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. CONCLUSIONS: Up to now, no published data from randomized clinical studies have addressed the question of efficacy of everolimus as a third-line treatment after failure of tyrosine kinase inhibitors. To the best of our knowledge, this case is the first report of chromophobe renal cell carcinoma treated successfully with sequential tyrosine kinase and mammalian target of rapamycin inhibitor therapy. Notably, the time on treatment with sunitinib exceeded four years. The case presented here implies that everolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.
format Online
Article
Text
id pubmed-3350425
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33504252012-05-12 Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report Michalaki, Vasiliki Gennatas, Constantine J Med Case Reports Case Report INTRODUCTION: Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Current strategies are based on results obtained in the context of clear cell-type renal cell carcinoma. Separate trials for rare histologies seem unfeasible and are unlikely to be performed. For these cases, clinical observations are an important part for advancing therapeutic insight. In recent years, novel tyrosine kinase inhibitors have been shown to have significant clinical benefit in advanced renal cell carcinoma. CASE PRESENTATION: We present the case of a 43-year-old Caucasian man with advanced chromophobe renal cell carcinoma treated with the tyrosine kinase inhibitor sunitinib and subsequently with sorafenib and the mammalian target of the rapamycin inhibitor everolimus, achieving a prolonged response and significant clinical benefit. We report an unexpectedly high efficacy of everolimus as a third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. CONCLUSIONS: Up to now, no published data from randomized clinical studies have addressed the question of efficacy of everolimus as a third-line treatment after failure of tyrosine kinase inhibitors. To the best of our knowledge, this case is the first report of chromophobe renal cell carcinoma treated successfully with sequential tyrosine kinase and mammalian target of rapamycin inhibitor therapy. Notably, the time on treatment with sunitinib exceeded four years. The case presented here implies that everolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma. BioMed Central 2012-04-23 /pmc/articles/PMC3350425/ /pubmed/22524151 http://dx.doi.org/10.1186/1752-1947-6-115 Text en Copyright ©2012 Michalaki and Gennatas; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Michalaki, Vasiliki
Gennatas, Constantine
Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
title Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
title_full Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
title_fullStr Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
title_full_unstemmed Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
title_short Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
title_sort chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350425/
https://www.ncbi.nlm.nih.gov/pubmed/22524151
http://dx.doi.org/10.1186/1752-1947-6-115
work_keys_str_mv AT michalakivasiliki chromophoberenalcellcarcinomawithprolongedresponsetotargetedtherapyacasereport
AT gennatasconstantine chromophoberenalcellcarcinomawithprolongedresponsetotargetedtherapyacasereport